[go: up one dir, main page]

MX2022000069A - Formas sólidas de (s)-2-((2s,3r)-1-amino-3-hidroxi-1-oxobutan-2-il )-1-oxo 2,5-diazaspiro[3.4]octano-5-carboxilato de terc-butilo y métodos para prepararlas. - Google Patents

Formas sólidas de (s)-2-((2s,3r)-1-amino-3-hidroxi-1-oxobutan-2-il )-1-oxo 2,5-diazaspiro[3.4]octano-5-carboxilato de terc-butilo y métodos para prepararlas.

Info

Publication number
MX2022000069A
MX2022000069A MX2022000069A MX2022000069A MX2022000069A MX 2022000069 A MX2022000069 A MX 2022000069A MX 2022000069 A MX2022000069 A MX 2022000069A MX 2022000069 A MX2022000069 A MX 2022000069A MX 2022000069 A MX2022000069 A MX 2022000069A
Authority
MX
Mexico
Prior art keywords
oxobutan
diazaspiro
octane
oxo
amino
Prior art date
Application number
MX2022000069A
Other languages
English (en)
Inventor
Shaoxin Feng
Xiaoda Yuan
William R Perrault
Danny T Dinh
Original Assignee
Naurex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Naurex Inc filed Critical Naurex Inc
Publication of MX2022000069A publication Critical patent/MX2022000069A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Formas en estado sólido de (S)-2-((2S,3R)-1-amino-3-hidroxi-1-oxob utan-2-il)-1-oxo 2,5-diazaspiro[3.4]octano-5-carboxilato de terc-butilo, composiciones farmacéuticas, preparación y usos de las mismas.
MX2022000069A 2019-06-24 2020-06-23 Formas sólidas de (s)-2-((2s,3r)-1-amino-3-hidroxi-1-oxobutan-2-il )-1-oxo 2,5-diazaspiro[3.4]octano-5-carboxilato de terc-butilo y métodos para prepararlas. MX2022000069A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962865826P 2019-06-24 2019-06-24
PCT/US2020/039163 WO2020263847A1 (en) 2019-06-24 2020-06-23 Solid forms of tert-butyl (s)-2-((2s,3r) -1-amino-3-hydroxy-1-oxobu tan-2-yl)-1-oxo-2, 5-diazaspiro [3.4] octan e-5-carboxylate and methods of preparing them

Publications (1)

Publication Number Publication Date
MX2022000069A true MX2022000069A (es) 2022-05-24

Family

ID=74060350

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2022000069A MX2022000069A (es) 2019-06-24 2020-06-23 Formas sólidas de (s)-2-((2s,3r)-1-amino-3-hidroxi-1-oxobutan-2-il )-1-oxo 2,5-diazaspiro[3.4]octano-5-carboxilato de terc-butilo y métodos para prepararlas.
MX2025002579A MX2025002579A (es) 2019-06-24 2022-01-03 Formas solidas de (s)-2-((2s,3r)-1-amino-3-hidroxi-1-oxobutan-2-il)-1-oxo-2,5-diazaspiro[3.4]octano-5-carboxilato de terc-butilo y metodos para prepararlas

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2025002579A MX2025002579A (es) 2019-06-24 2022-01-03 Formas solidas de (s)-2-((2s,3r)-1-amino-3-hidroxi-1-oxobutan-2-il)-1-oxo-2,5-diazaspiro[3.4]octano-5-carboxilato de terc-butilo y metodos para prepararlas

Country Status (12)

Country Link
US (1) US20220267341A1 (es)
EP (1) EP3986399A4 (es)
JP (2) JP7617043B2 (es)
KR (1) KR20220061088A (es)
CN (1) CN114364380A (es)
AU (1) AU2020304001A1 (es)
BR (1) BR112021026380A2 (es)
CA (1) CA3144600A1 (es)
IL (1) IL289198A (es)
MA (1) MA56550A (es)
MX (2) MX2022000069A (es)
WO (1) WO2020263847A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120004904A (zh) 2019-06-24 2025-05-16 诺雷克斯股份有限公司 生产二氮杂螺内酰胺化合物的方法和中间体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0323204D0 (en) * 2003-10-03 2003-11-05 Novartis Ag Organic compounds
EP2402326A1 (en) * 2005-06-21 2012-01-04 Ajinomoto Co., Inc. Crystals of hydrochloride salts of a Phenylalanine Derivative, Production Method Thereof and Use Thereof as alpha4 integrin Inhibitors
CA2740628C (en) * 2008-09-18 2018-05-01 Naurex, Inc. Nmda receptor modulators and uses thereof
KR20150110787A (ko) 2013-01-29 2015-10-02 노렉스, 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
HRP20190613T1 (hr) * 2013-01-29 2019-06-28 Aptinyx Inc. Spiro-laktam modulatori nmda receptora i njihove uporabe
TWI738748B (zh) * 2016-03-28 2021-09-11 日商武田藥品工業有限公司 2-[(2s)-1-氮雜雙環[2.2.2]辛-2-基]-6-(3-甲基-1h-吡唑-4-基)噻吩并[3,2-d]嘧啶-4(3h)-酮半水合物之晶形
CN109415372B (zh) * 2016-05-19 2021-01-15 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
CN120004904A (zh) 2019-06-24 2025-05-16 诺雷克斯股份有限公司 生产二氮杂螺内酰胺化合物的方法和中间体

Also Published As

Publication number Publication date
MX2025002579A (es) 2025-04-02
JP2022539342A (ja) 2022-09-08
KR20220061088A (ko) 2022-05-12
CN114364380A (zh) 2022-04-15
EP3986399A4 (en) 2023-06-07
BR112021026380A2 (pt) 2022-05-10
CA3144600A1 (en) 2020-12-30
WO2020263847A1 (en) 2020-12-30
US20220267341A1 (en) 2022-08-25
JP2025069143A (ja) 2025-04-30
AU2020304001A1 (en) 2022-01-27
IL289198A (en) 2022-02-01
EP3986399A1 (en) 2022-04-27
MA56550A (fr) 2022-04-27
JP7617043B2 (ja) 2025-01-17

Similar Documents

Publication Publication Date Title
EP4512399A3 (en) Solid state forms of tafamidis and salts thereof
MX2020001598A (es) Inhibidores selectivos de proteína arginina metiltransferasa 5 (prmt5).
CL2012002355A1 (es) Compuestos derivados de 1,3,4,8-tetrahidro-2h-pirido[1,2-a]pirazina; composicion farmaceutica que los comprende; kit farmaceutico; y su uso como inhibidores de la integrasa del vih para el tratamiento de una enfermedad infecciosa del vih.
MA40236A (fr) Formes cristallines de (2r,5s,13ar)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-méthanpyrido[1',2':4,5]pyrazino 2,1-b][1,3]oxazépine-10-carboxamide
PH12020550703A1 (en) Sulfonamide compounds and use thereof
MX2019004611A (es) Metodos y composiciones para cambiar la composicion del microbioma de la piel usando mezclas complejas de cepas bacterianas.
BR112015032736A2 (pt) inibidores de bromodomínio cristalino
NZ721952A (en) Delayed release compositions of linaclotide
BR112015018087A8 (pt) composto, composição farmacêutica e uso
EP4414376A3 (en) Novel depsipeptide and uses thereof
BR112018071831A2 (pt) composições anti-irritantes sinérgicas de taurina e aloé e métodos
PH12021550048A1 (en) Selective estrogen receptor degraders.
UY34008A (es) ?formas en estado sólido de inhibidor de hiv, composición farmacéutica, uso de la misma, y procesos para preparar dichas formas?.
MX391152B (es) Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas.
ZA202005325B (en) Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2019078968A3 (en) Cyclic compounds as immunomodulating agents
PH12020550537A1 (en) Bicyclic sulfones and sulfoxides and methods of use thereof
WO2020127819A3 (en) Pharmaceutical composition comprising apixaban
EP4272832A3 (en) Antimicrobial compounds, compositions, and uses thereof
AU2019366996A8 (en) Polymer-lipids and compositions
SA520420261B1 (ar) تركيبات إرنوماب واستخداماتها
UA113540C2 (xx) Поліморфи n-(2-метоксибензоїл)-4-$(метиламінокарбоніл)аміно]бензолсульфонаміду
MX2021005910A (es) Formulacion de proteina de alta concentracion.
MX2022000069A (es) Formas sólidas de (s)-2-((2s,3r)-1-amino-3-hidroxi-1-oxobutan-2-il )-1-oxo 2,5-diazaspiro[3.4]octano-5-carboxilato de terc-butilo y métodos para prepararlas.
UY37261A (es) Formulación combinada de tres compuestos antivirales